Medicenna Therapeutics Corp Stock Performance
| MDNA Stock | CAD 1.77 0.10 5.99% |
The company secures a Beta (Market Risk) of -0.23, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Medicenna Therapeutics are expected to decrease at a much lower rate. During the bear market, Medicenna Therapeutics is likely to outperform the market. At this point, Medicenna Therapeutics has a negative expected return of -0.19%. Please make sure to verify Medicenna Therapeutics' coefficient of variation, jensen alpha, treynor ratio, as well as the relationship between the standard deviation and total risk alpha , to decide if Medicenna Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Medicenna Therapeutics Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's basic indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors. ...more
Last Split Factor 1:14 | Dividend Date 2017-03-03 | Last Split Date 2017-03-03 |
1 | OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX - GlobeNewswire | 10/15/2024 |
2 | Medicennas MDNA11 Drug Shows 30 percent Response Rate, Strong Results in Cancer Trial MDNAF Stock News - StockTitan | 11/15/2024 |
| Begin Period Cash Flow | 33.6 M |
Medicenna |
Medicenna Therapeutics Relative Risk vs. Return Landscape
If you would invest 218.00 in Medicenna Therapeutics Corp on August 29, 2024 and sell it today you would lose (41.00) from holding Medicenna Therapeutics Corp or give up 18.81% of portfolio value over 90 days. Medicenna Therapeutics Corp is generating negative expected returns and assumes 5.3692% volatility on return distribution over the 90 days horizon. Simply put, 47% of stocks are less volatile than Medicenna, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Medicenna Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medicenna Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Medicenna Therapeutics Corp, and traders can use it to determine the average amount a Medicenna Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0347
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MDNA |
Estimated Market Risk
| 5.37 actual daily | 47 53% of assets are more volatile |
Expected Return
| -0.19 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Medicenna Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Medicenna Therapeutics by adding Medicenna Therapeutics to a well-diversified portfolio.
Medicenna Therapeutics Fundamentals Growth
Medicenna Stock prices reflect investors' perceptions of the future prospects and financial health of Medicenna Therapeutics, and Medicenna Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Medicenna Stock performance.
| Return On Equity | -1.05 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 98.41 M | ||||
| Shares Outstanding | 78.16 M | ||||
| Price To Book | 6.42 X | ||||
| EBITDA | (18.67 M) | ||||
| Net Income | (25.47 M) | ||||
| Cash And Equivalents | 33.6 M | ||||
| Cash Per Share | 0.83 X | ||||
| Total Debt | 13.94 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 26.75 X | ||||
| Book Value Per Share | 0.07 X | ||||
| Cash Flow From Operations | (16.26 M) | ||||
| Earnings Per Share | (0.38) X | ||||
| Market Capitalization | 138.34 M | ||||
| Total Asset | 19.13 M | ||||
| Retained Earnings | (106.45 M) | ||||
| Working Capital | 16.21 M | ||||
About Medicenna Therapeutics Performance
By examining Medicenna Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Medicenna Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Medicenna Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.33) | (1.40) | |
| Return On Capital Employed | (1.21) | (1.15) | |
| Return On Assets | (1.33) | (1.40) | |
| Return On Equity | (4.91) | (4.66) |
Things to note about Medicenna Therapeutics performance evaluation
Checking the ongoing alerts about Medicenna Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Medicenna Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Medicenna Therapeutics generated a negative expected return over the last 90 days | |
| Medicenna Therapeutics has high historical volatility and very poor performance | |
| Medicenna Therapeutics may become a speculative penny stock | |
| Medicenna Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (25.47 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Medicenna Therapeutics Corp has accumulated about 33.6 M in cash with (16.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.83. | |
| Roughly 22.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Medicennas MDNA11 Drug Shows 30 percent Response Rate, Strong Results in Cancer Trial MDNAF Stock News - StockTitan |
- Analyzing Medicenna Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medicenna Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Medicenna Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Medicenna Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medicenna Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Medicenna Therapeutics' stock. These opinions can provide insight into Medicenna Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Medicenna Stock
Medicenna Therapeutics financial ratios help investors to determine whether Medicenna Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medicenna with respect to the benefits of owning Medicenna Therapeutics security.